Trial of Aripiprazole in the Treatment of CD in Adolescents

Completed · Phase 4

Conditions studied: Conduct Disorder

In brief

The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder. The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). For the first two weeks of the study, the dose will be flexible based on response and tolerance and thereafter will remain fixed.

Key facts

Study ID

NCT00250705

Run by

University of Iowa

People needed

12

Starts

2004-11-17

Expected to finish

2009-03-23

Last updated by the study team

2017-07-11

Who can join

Age: 13 and older, up to 17. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder.

You may not qualify if…

• Clinically significant laboratory and/or ECG abnormalities
• Pre-existing health conditions that would compromise patient safety
• Mental retardation
• Previous use of aripiprazole
• Active psychosis

Where it is running

• The University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.